Global Business Reports


Neha Ghanshamdas, Vanessa Benz, JP Stevenson

Spain Pharmaceuticals 2015

October 09, 2015

Spain is home to well-established and heavily regulated pharmaceutical and biotechnological industries, concentrated primarily in the capital city of Madrid and the eastern autonomous community of Catalonia. While Madrid has hosted many of the world’s multinational pharmaceutical giants for years—including Novartis, GlaxoSmithKline, Roche, Sanofi, and AstraZeneca—the country’s northeastern region has fostered the development of Spanish multinational players such as Esteve, Almirall, Ferrer, and Grifols. Today, Spain is the fifth largest European pharmaceutical market, with the sector accounting for 1.4% of the country’s total GDP. The industry’s longstanding relevance parallels the country’s world renowned National Health System, which consistently ranks highly among its peers. In 2014, Bloomberg ranked Spain as the world’s 14th most efficient health care system, far ahead of the United States and Canada.

Since the economic crisis of 2008, however, Spain’s expenditure on healthcare has progressively declined, placing the nation well behind its fellow OECD countries. Prior to the economic crisis, Spain was a leader in healthcare investment, spending up to €64.3 billion in the sector in 2009, compared with €53.5 billion in 2014. Furthermore, spending cuts have not been consistent across the country, creating causes for concern over the rise of regional inequities. The Spanish government has implemented a series of cost-saving measures, presenting financial concerns to the industry at large.


Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.


Chile Mining 2024 Pre-Release

The Chilean mining renaissance has begun. In 2024, the country is set to experience its first increase in copper production since 2018, driven by Codelco’s production surge and Teck Resources’ Quebrada Blanca II coming online. This year also saw the first major regulatory update since 1983 with amendments to Law No. 21,420, which modernized the mining framework. The government has shown strong support for the industry by committing to reduce permit processing times by a third and proposing 20 actionable measures to streamline processes. Additionally, Chile classified its 69 saline environments, leaving 31 open for private development and initiating a request for information process in April to rapidly advance these areas.



"We plan to double our copper production by the end of the decade. There remains significant upside potential in the gold industry, and the copper operations are strategic and additive to that."